JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Fechado

SetorSaúde

4.42 -3.49

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.35

Máximo

4.55

Indicadores-chave

By Trading Economics

Rendimento

-39M

-44M

Vendas

9.8M

62M

Margem de lucro

-70.929

Funcionários

702

EBITDA

4M

-263K

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+40.13% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

12M

573M

Abertura anterior

7.91

Fecho anterior

4.42

Sentimento de Notícias

By Acuity

50%

50%

177 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Cytek Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de abr. de 2026, 23:33 UTC

Ações em Alta

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 de abr. de 2026, 23:24 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 de abr. de 2026, 22:46 UTC

Ganhos

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 de abr. de 2026, 22:37 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 de abr. de 2026, 22:15 UTC

Ganhos
Notícias Principais

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 de abr. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 de abr. de 2026, 23:19 UTC

Conversa de Mercado
Ganhos

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 de abr. de 2026, 23:09 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 de abr. de 2026, 22:51 UTC

Ganhos

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 de abr. de 2026, 22:40 UTC

Conversa de Mercado
Notícias Principais

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 de abr. de 2026, 22:32 UTC

Ganhos

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 de abr. de 2026, 22:22 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 de abr. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparação entre Pares

Variação de preço

Cytek Biosciences Inc Previsão

Preço-alvo

By TipRanks

40.13% parte superior

Previsão para 12 meses

Média 6.25 USD  40.13%

Máximo 7.5 USD

Mínimo 5 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Cytek Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.7 / 3.8Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

177 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat